Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
Authors:
- For the German Dermatologic Cooperative Oncology Group (DeCOG)F(For the German Dermatologic Cooperative Oncology Group (DeCOG)
- Katharina C. KählerKKKatharina C. Kähler
- 27 February 2018
- journal article
- research article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 67 (5) , 825-834
Abstract
Ipilimumab and programmed death (PD) 1-antibodies are effective treatment options in metastatic melanoma. The safety and efficacy of ipilimumab in patients with pre-existing autoimmune disorders (AD) has only been evaluated in a selected number of patients.Keywords
This publication has 19 references indexed in Scilit:
- Pembrolizumab Cutaneous Adverse Events and Their Association With Disease ProgressionJAMA Dermatology, 2015
- Rapid complete response of metastatic melanoma in a patient undergoing ipilimumab immunotherapy in the setting of active ulcerative colitisJournal for ImmunoTherapy of Cancer, 2015
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2015
- Ipilimumab in patients with melanoma and autoimmune diseaseJournal for ImmunoTherapy of Cancer, 2014
- Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune diseaseCancer Immunology, Immunotherapy, 2014
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab NetworkPLOS ONE, 2013
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4Journal of Clinical Oncology, 2005